

59 - References

References

Bipolar disorder CHAPTER 2 References

1. Malhi GS, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders: bipolar disorder summary. *Bipolar Disord* 2020; 22:805–821.
2. Yatham LN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. *Bipolar Disord* 2018; 20:97–170.
3. Kang MG, et al. Lithium vs valproate in the maintenance treatment of bipolar I disorder: a post-hoc analysis of a randomized double-blind placebo-controlled trial. *Aust NZ J Psychiatry* 2020; 54:298–307.
4. Solomon DA, et al. Longitudinal course of bipolar I disorder: duration of mood episodes. *Arch Gen Psychiatry* 2010; 67:339–347.
5. Perlis RH, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). *Am J Psychiatry* 2006; 163:217–224.
6. Goodwin GM, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. *J Psychopharmacol* 2016; 30:495–553.
7. Nestsiarovich A, et al. Preventing new episodes of bipolar disorder in adults: systematic review and meta-analysis of randomized controlled trials. *Eur Neuropsychopharmacol* 2022; 54:75–89.
8. Sani G, et al. Treatment of bipolar disorder in a lifetime perspective: is lithium still the best choice? *Clin Drug Investig* 2017; 37:713–727.
9. Hartong EG, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naïve bipolar patients. *J Clin Psychiatry* 2003; 64:144–151.
10. Cipriani A, et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. *Cochrane Database Syst Rev* 2013; 10:CD003196.
11. Geddes JR, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. *Lancet* 2010; 375:385–395.
12. Kemp DE, et al. A 6-month, double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. *J Clin Psychiatry* 2009; 70:113–121.

13. Smith LA, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. *Bipolar Disord* 2007; 9:394-412.
14. Cipriani A, et al. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. *Am J Psychiatry* 2005; 162:1805-1819.
15. Kessing LV, et al. Suicide risk in patients treated with lithium. *Arch Gen Psychiatry* 2005; 62:860-866.
16. Song J, et al. Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50,000 patients with bipolar disorder. *Am J Psychiatry* 2017; 174:795-802.
17. Mander AJ, et al. Rapid recurrence of mania following abrupt discontinuation of lithium. *Lancet* 1988; 2:15-17.
18. Faedda GL, et al. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. *Arch Gen Psychiatry* 1993; 50:448-455.
19. Macritchie KA, et al. Does 'rebound mania' occur after stopping carbamazepine? A pilot study. *J Psychopharmacol* 2000; 14:266-268.
20. Franks MA, et al. Bouncing back: is the bipolar rebound phenomenon peculiar to lithium? A retrospective naturalistic study. *J Psychopharmacol* 2008; 22:452-456.
21. Kessing LV, et al. Starting lithium prophylaxis early v. late in bipolar disorder. *Br J Psychiatry* 2014; 205:214-220.
22. Kessing LV, et al. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. *Br J Psychiatry* 2011; 199:57-63.
23. Gao K, et al. Typical and atypical antipsychotics in bipolar depression. *J Clin Psychiatry* 2005; 66:1376-1385.
24. Hellewell JS. A review of the evidence for the use of antipsychotics in the maintenance treatment of bipolar disorders. *J Psychopharmacol* 2006; 20:39-45.
25. Gigante AD, et al. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. *CNS Drugs* 2012; 26:403-420.
26. Tohen M, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. *Am J Psychiatry* 2003; 160:1263-1271.
27. National Institute for Health and Care Excellence. Bipolar disorder: assessment and management. Clinical guideline [CG185]. 2014 (last updated December 2023, last accessed October 2024); <https://www.nice.org.uk/guidance/cg185>.
28. Vieta E, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). *J Affect Disord* 2008; 109:251-263.
29. McIntyre RS. Aripiprazole for the maintenance treatment of bipolar I disorder: a review. *Clin Ther* 2010; 32 Suppl 1:S32-S38.
30. Ghaemi SN, et al. Long-term risperidone treatment in bipolar disorder: 6-month follow up. *Int Clin Psychopharmacol* 1997; 12:333-338.
31. Szegedi A, et al. Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. *Am J Psychiatry* 2017; 175:71-79.

32. Bowden CL, et al. Efficacy of valproate versus lithium in mania or mixed mania: a randomized, open 12-week trial. *Int Clin Psychopharmacol* 2010; 25:60–67.
33. Calabrese JR, et al. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. *Eur Neuropsychopharmacol* 2017; 27:865--876.
34. McIntyre RS, et al. The efficacy of lumateperone in patients with bipolar depression with mixed features. *J Clin Psychiatry* 2023; 84:22m14739.
35. McIntyre RS, et al. Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder. *Bipolar Disord* 2024; 26:442–453.
36. Kishi T, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta- analysis of randomized controlled trials. *Mol Psychiatry* 2021; 26:4146–4157.
37. Escudero MAG, et al. Second generation antipsychotics monotherapy as maintenance treatment for bipolar disorder: a systematic review of long-term studies. *Psychiatr Q* 2020; 91:1047–1060.

330 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 2

38. Calabrese JR, et al. Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal study. *J Clin Psychiatry* 2017; 78:324–331.
39. Kishi T, et al. Long-acting injectable antipsychotics for prevention of relapse in bipolar disorder: a systematic review and meta-analyses of randomized controlled trials. *Int J Neuropsychopharmacol* 2016; 19:pyw038.
40. Hsieh MH, et al. Bipolar patients treated with long-acting injectable risperidone in Taiwan: a 1-year mirror-image study using a national claims database. *J Affect Disord* 2017; 218:327–334.
41. Belge JB, et al. Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review. *Expert Opin Pharmacother* 2024; 25:295–299.
42. Kishi T, et al. A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: a systematic review. *Psychiatry Res* 2024; 333:115761.
43. Pacchiarotti I, et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: a systematic review. *Eur Neuropsychopharmacol* 2019; 29:457–470.
44. Yıldızhan E, et al. Effect of long acting injectable antipsychotics on course and hospitalizations in bipolar disorder – a naturalistic mirror image study. *Nord J Psychiatry* 2022; 76:37–43.
45. Nolen WA, et al. What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium. *Bipolar Disord* 2019; 21:394–409.
46. Freeman MP, et al. Mood stabilizer combinations: a review of safety and efficacy. *Am J Psychiatry* 1998; 155:12–21.
47. Muzina DJ, et al. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. *Aust NZ J Psychiatry* 2005; 39:652–661.
48. Tohen M, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. *Br J Psychiatry* 2004; 184:337–345.
49. Paton C, et al. Lithium in bipolar and other affective disorders: prescribing practice in the UK. *J Psychopharmacol* 2010; 24:1739–1746.
50. Marcus R, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. *Bipolar Disord* 2011; 13:133–144.
51. Bowden CL, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. *Arch Gen Psychiatry* 2003; 60:392–400.
52. Pikalov A, et al. Long-term use of lurasidone in patients

with bipolar disorder: safety and effectiveness over 2 years of treatment. *Int J Bipolar Disord* 2017; 5:9. 53. Wingård L, et al. Monotherapy vs. combination therapy for post mania maintenance treatment: a population based cohort study. *Eur Neuropsychopharmacol* 2019; 29:691–700. 54. Jauhar S, et al. Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. *Int J Bipolar Disord* 2019; 7:10. 55. Ghaemi SN, et al. Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks. *Acta Psychiatr Scand* 2008; 118:347–356. 56. Ghaemi SN, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. *J Clin Psychiatry* 2010; 71:372–380. 57. Yatham LN, et al. Duration of adjunctive antidepressant maintenance in bipolar I depression. *N Engl J Med* 2023; 389:430–440.

Revision #1

Created 2026-01-04 20:14:32 UTC by Omar Ayman

Updated 2026-01-04 20:14:33 UTC by Omar Ayman